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The presence ofblue-green algae (BGA) toxins in surface waters used for drinking water sources
and recreation is receiving increasing attention around the world as a public health concern.
However, potential risks from exposure tothese toxins in contaminated health foodproducts that
contain BGA have been largly ignored. BGA products are commonly consumed in the United
States, Cnada, and Europe for their putative beneficial effects, including increased ener and
elevatedmood. Manyoftheseproducts containAphanizomenonfios-aquae, aBGAthat is harvest-
ed from Upper Klamath Lake (UIKL) in southern Oregon, where the growth of a toxic BGA,
Microcystis amrginosa, is a regular occurrence. M. aersginosa produces compounds called micro-
cystins, which are potent hepatotoxins and probable tumor promoters. Because M. aeruginosa
coexists with A.flos-aquae, it can be collected inadvertently during the harvesing process, result-
ing in microcystin contamination of BGA products. In all 1996, the Oregon Health Division
learned that UKLwas experiencing anextensive M. aeruginosabloom, andanadvisorywas issued
recommending againstwatercontact. The advisoryprompted calls from consumers ofBGAprod-
ucts,who expressedconcern aboutpossible contamination oftheseproductswithmicrocystins. In
response, the Oregon Health Division and the Oregon Department ofAgriculture established a
regulatorylimit of 1 p/gformicrocystins inBGA-containing products and tested BGAproducts
for the presence ofmicrocystins. Microcystins were detected in 85 of87 samples tested, with 63
samples (72%) containing concentrations > 1 pglg. HPLC and ELISA tentatively identified
microcystin-LR, the most toxic microcystin variant, as the predominant congener. Ke wordk:
Aphaniwomenonflos-aquae, blue-green algae, cyanobacteria, dietary supplements, microcystins,
Microcystis.aruginosaz EnvironHealfhPerpect108:435439 (2000). [Online 27 March 2000]
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The presence of toxic cyanobacteria
(blue-green algae) in surface waters used for
drinkingwatersources and recreation is receiv-
ing increasing attention worldwide as a poten-
tial health concern (1-5). Human illness
resulting from exposure to blue-green algal
toxins, though less common than poisonings
ofwild and domestic animals (6-5), has been
reported (1,2,10-12). In 1996, 55 hemodialy-
sis patients died in Brazil when the dialysis
water became contaminated with toxins from
theblue-green alga Microcystisaeruginosa (13).
Although potential health risks from
exposure to algal toxins in surface waters
have been widely recognized, potential risks
from exposure through another important
route-ingestion of contaminated dietary
supplements made from blue-green algae
(BGA)-have received only limited atten-
tion (2,3,6,14). Because of its concentrated
form, the exposure potential to algal toxins
in contaminated BGA products can greatly
exceed potential exposure through water
consumption or recreational contact.
Since 1983, the blue-green alga Apha-
nizomenon Jlos-aquae has been harvested
from Upper Klamath Lake (UKL) in south-
ern Oregon and marketed as a dietary sup-
plement. These supplements are commonly
consumed in the United States, Canada, and
Europe for their putative beneficial effects,
including "detoxification," increased energy,
elevated mood, and weight loss. They are
also marketed for use in children and are
used as a treatment for Attention Deficit
Hyperactivity Disorder (15).
In September 1996, the Oregon Health
Division (OHD) in Portland, Oregon, learned
that UKL was experiencing an extensive
bloom ofM aeruginosa, a blue-green alga that
produces potent hepatotoxins called micro-
cystins. An investigation revealed that the M
aeruginosa bloom had resulted in significant
microcystin levels in the lake, and an advisory
was issued recommending against water con-
tact. The advisory prompted calls from con-
sumers ofUKL BGA products, who expressed
concern about the possible contamination of
these products with microcystin toxins. In
response to these concerns, the OHD and the
Oregon Department ofAgriculture (ODA;
Salem, OR) tested BGA-containing supple-
ments for microcystins and derived a regulato-
rystandard for microcystins in BGA products.
In this paper we discuss the rationale for
Oregon's microcystin standard and report
analytical test results that clearly indicate the
need for regulatory control ofBGA products.
Materials and Methods
Materials. Microcystin-leucine-arginine
variant [microcystin-LR (MCYST-LR)] was
provided byW.W. Carmichael (Wright State
University, Dayton, OH). We obtained
ELISA-grade horseradish peroxidase (HRP)
from Boehringer Mannheim Biochemicals
(Indianapolis, IN). We prepared polyclonal
antibodies against MCYST-LR used in an
ELISA as previously described (16). MCYST-
HRP conjugate was prepared according to the
method of Chu et al. (16). The antibodies
used in the assay were most specific for
MCYST-LR (100%) and arginine-arginine
variant (MCYST-RR; 126%), with some
cross-reactivity with tyrosine-arginine variant
(MCYST-YR; 65%) and nodularin (48%)
(16). K-B substrate solution (a premixed
solution with 1 mM 3,3',5,5'-tetramethyl-
benzidine and 3 mM H202 potassium citrate
buffer, pH 3.9) was supplied by ELISA
Technologies (Lexington, KY). Sep-Pak C-
18 reversed-phase cartridges were from
Waters Associates (Milford, MA). All other
chemicals and organic solvents were of
reagent grade or better.
Product testing. In 1996 and 1997,
OHD investigators obtained 61 product
samples (tablets or capsules) from the four
primary UKL BGA harvesters. The samples
were obtained from various Oregon retail
outlets or directly from the harvesters.
Fifteen samples of Spirulina (a commonly
consumed BGA that is not from UKL) and
26 additional UKL BGA samples were
obtained by ODA investigators in 1998
and 1999.
A competitive direct-ELISA (cd-ELISA)
was used for the analysis ofMCYST content
in BGA samples according to the protocol of
Chu et al. (1/). Typically, 0.5-1 g ofa well-
mixed algae sample was homogenized with
50 volumes 0.1 M ammonium bicarbonate
in a tissue homogenizer for 3 min. For
tablets, two randomly selected samples were
first ground with a mortar; 0.5 g ofthe mixed
sample was used. After homogenization and
centrifugation (30 min at 16,000 x g) to
remove the cell debris or solid materials,
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we diluted the supernatant 10 and 100 times
with distilled water and then subjected it to
the cd-ELISA using the protocol previously
described by Chu et al. (17). At least two
analyses were performed for each sample, and
triplicates were run for each analysis. The
intrawell coefficient ofvariation of the same
sample extract in the triplicates was generally
< 10%. The analytical recovery of MCYST-
LR added to the blank algae extract sample
(1-20 pg/g) in the ELISAwas > 70% (17).
Because ofthe known heterogeneous dis-
tribution of M aeruginosa and microcystin
toxin in lake environments (18) and the con-
sequent potential implications for quality
assurance of BGA products, we also tested
BGA samples for microcystin homogeneity.
We evaluated homogeneity in twoways: a) by
comparing the microcystin content ofa single
tablet or capsule from a product container
with a composite tablet/capsule from the
same container; and b) by comparing micro-
cystin concentrations in samples from differ-
ent product containers from the same batch
(i.e., thosehavingthe same batch number).
To further elaborate on the ELISA data
from the BGA samples, two samples were
subjected to HPLC separation and ELISA
analysis ofthe collected fractions. We used a
Sphereclone ODS C-18 reversed-phase col-
umn (4.6 mm x 25 cm; Phenomenex,
Torrance, CA) and a Beckman model 100 A
HPLC system (Beckman, Fullerton, CA)
equipped with a 412A controller for the
analysis. In a typical experiment, extracts pre-
pared from a 3-g sample (1 g each time with
30 mL ofbuffer) were pooled, diluted with
water (1:10), and subjected to a C-18
reversed-phase Sep-Pak column, as previously
described (17). After washing with distilled
water and 20% methanol, microcystin was
eluted from the column with 3 mL 100%
methanol, which was evaporated to dryness
and redissolved in 0.2 mL methanol followed
by 0.8 mL distilled water. The recovery of
MCYST-LR in algal extract after Sep-Pak
treatment was generally > 88%, in the range
of 1-63 pg/mL (17). For HPLC, 50 ,L of
this solution was diluted with 50 pL 0.02 M
phosphate-buffered saline (PBS) and 10-50
1L (depending on toxin concentration) ofthe
diluted solution was injected into the column.
The column was equilibrated with solvent A
[CH OH.H2O: TFA (20:80:0.025), vol/vol]
at adow rate of 1 mL/min. Five minutes after
the injection ofsamples, weapplied agradient
elution starting from 100% A to 100% B
[CH3OH:H20: TFA (90:10:0.025), vol/vol]
overa periodof20 min. This was followed by
solvent B for another 20 min, and finally by
100% solvent A over a period of 20 min
before the next injection. Each fraction (0.5
mL/fraction) collected from the HPLC col-
umn was diluted (1:1000) with PBS and then
subjected to the ELISA.
Derivation ofa maximum allowable
concentration for microcystins. We used
established risk assessment methodology (19(
to develop a tolerable daily intake (TDI) and
a maximum allowable concentration for
microcystins in BGA products. The TDI was
based on a no-observed-adverse-effect level
(NOAEL) for microcystin-LR in mice (20)
with the application of standard uncertainty
factors (UFs) (19). The approach is similar to
that used recently by Health Canada (21)
and the World Health Organization (22) to
develop guideline levels for microcystins in
drinking water.
Results
ELISA standard curve. A typical standard
curve for ELISA analysis of MCYST-LR is
shown in Figure 1. Although the standard
curve covered a range from 0.02 to 5.0
ng/mL, data within the linear range of the
curve (0.05-1.0 ng/mL) were the most accu-
rate. Initial screening found that 1:10 and
1:100 PBS dilutions were sufficient for most
samples to fall within the linear range. All
diluted sample solutions were again subject-
ed to ELISA to ensure that the data were
within the linear range.
Product testing. Analytical results for
microcystins in BGA products collected
between 1996 and 1999 are shown in Table
1. The average MCYST levels in the sam-
ples collected by OHD investigators from
the four primary harvesters in 1996 and
1997 ranged from 2.15 to 10.89 pg/g.
Microcystin concentrations in ODA sam-
ples collected in May 1998 were generally
similar to OHD sampling results. Lower
concentrations were observed in samples
collected inJanuary 1999.
We observed differences between indi-
vidual and composite samples from the same
BGA product containers, although in most
cases (21 of 29) the variation was < 30%
(data not shown). Three samples showed
substantial variation (53, 76, and 99%),
indicating that microcystin heterogeneity
can occur in some BGA products. We
observed similar results when we compared
microcystin concentrations in different
product containers from the same batch
(Table 2). Variation of the paired analyses
ranged from 13 to 63%. The largest varia-
tion (0.3 and 0.78 pg/g) was found in batch
sample 4, which had levels close to the pre-
sent ELISA detection limit. In the other
paired samples the variation was < 30%;
however, a third sample from one batch
(batch 5) showed a markedly lower micro-
cystin concentration than the two other sam-
ples (< 0.04 pg/g as compared to 3.02 and
4.41 l'g/g), again indicating that microcystin
heterogeneity can occur in BGA products.
Two algal samples were subjected to
HPLC-ELISA. Results of a representative
activity profile of the 0.5 mL fractions are
shown in Figure 2. Figure 2B shows a major
inverse peakwith a retention time of25 min
and a minor inverse peak with a retention
time of 21.4 min when 10 ,uL BGA extract
(15 mg BGA) was injected and anti-
MCYST-LR antibodies were used in the
ELISA. The injection of standard MCYST-
LR and MCYST-RR separately into the col-
umn resulted in single inverse peaks with
retention times of 25 and 22 min, respec-
tively (data not shown), which is consistent
with our earlier studies (23). Thus, in terms
of activity, we identified the large inverse
peak in the ELISA-HPLC chromatogram as
MCYST-LR and the minor inverse peak as
MCYST-RR. Using the ELISA standard
curve, we estimated the MCYST-LR con-
centration in each fraction; the results are
shown in Figure 2A (positive peak). The
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Figure 1. ELISA standard curve for the analysis of
microcystin-LR.
Table 1. Microcystin concentrations in UKL blue-green algae dietary supplements.a
Harvester
Sample date A B C D
1996 10.06 ±7.42b 5.68 ± 4.83 2.15 ± 1.81 2.73 ± 3.32
(2.5-18.4; 8)C (0.04-16.36; 14) (0.36-3.76; 4) (0.16-7.84; 6)
1997 10.89 ± 5.37 6.67 ± 5.64 2.60 ± 2.89 4.30 ± 2.24
(0.22-15.2; 6) (0.41-16.44; 10) (0.16-7.96; 8) (1.26-6.79; 5)
1998 16.42d e 1.76 ±2.29 7.46 ± 2.16
(0.3-6.38; 6) (3.83-9.1; 5)
1999 2.65 ± 2.81 2.00 ± 1.90 0.43 ± 0.44 2.38
(0.4-6.58; 4) (0-4.14; 5) (0-0.87; 3) (0-4.75; 2)
'Samples were obtained by the OHD (Nov-Dec 1996 and Aug-Dec 1997) and by the ODA (May 1998 and January 1999).
1Values are means ± SD; microcystin concentration is given in micrograms per gram. cValues in parentheses are range
and number (n) of samples analyzed. dOnly one sample was analyzed. "No sample was analyzed.
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total concentration of MCYST-LR in this
peak was estimated at 21 ng. Because the
antibody has a higher cross-reaction with
MCYST-RR (126%) than with -LR (100%),
the -RRpeakappears to belarge; however, the
actual amount, estimated as MCYST-LR, was
much less (approximately 1.8 ng). Thus, even
though MCYST-RR was present, > 90% of
the microcystin was the -LR variant. Similar
data were obtained for the other sample,
which also contained predominantly -LR
(24.2 ng) withsmall amounts of-RR (1.0 ng).
These results are consistent with previous
work by others (24) using amino acid analy-
sis and mass spectrometry that showed the
predominant microcystins in UKL BGA are
MCYST-LR and MCYST-LA. MCYST-LA
has verylittle (< 2%) cross-reactivity with the
MCYST-LRantibody (16). Because the toxic
potency of MCYST-LA and MCYST-LR is
believed to be similar (25,26), it is likely that
use of the ELISA for analyzing microcystins
in BGA products underestimates the pres-
enceoftoxic microcystins to some extent.
Mean MCYST-LR concentrations in
Spirulina products obtained by ODA inves-
tigators in May 1998 andJanuary 1999 were
0.15 and 0.52 jig/g, respectively (Table 3).
Although the average microcystin concen-
trations were low, one sample contained
2.12 pg/g.
Microcystin TDI and regulatory stan-
dard. We derived the microcystin TDI by
applying three 10-fold UFs to the MCYST-
LR NOAEL of40 pg/kg-day established by
Table 2. Microcystin concentrations in two UKL
blue-green algae samples from each of six
batches.
Batch no. MCYST(pg/g) Mean SD %
1 3.56; 2.69 3.13 0.62 19.81
2 10.42; 6.98 8.70 2.43 27.93
3 3.02; 2.52 2.77 0.35 12.64
4 0.78; 0.30 0.54 0.34 62.96
5 3.02; 4.41a 3.72 0.98 26.34
6 6.02; 7.22 6.62 0.85 12.84
aThe MCYST concentration in a third sample from this
batch, obtained by the ODA in January 1999, was below











Fawell et al. (20), as follows: a 10-fold factor
for extrapolation from animal studies to
humans; a 10-fold factor for varying suscep-
tibility in the human population; and a 10-
fold factor to account for a) subchronic to
chronic extrapolation; b) evidence for tumor
promotion; and c) database inadequacies
(e.g., thelackofa reproductive study).
Thus, a 1,000-fold total UF was applied
to theNOAELof40 pg/kg-day to give aTDI
of0.04 pg/kg-day. Applying this result to a
60-kg adult results in 0.04 pg/kg-day x 60 kg
= 2.4 pg/day. Assuming a 2-g/day BGA con-
sumption rate (based on product literature
and discussions with BGA producers and
consumers), 2.4 pg/day÷2 g BGA/day = 1.2
pg/g = 1.0 pg/g. Thus, for adults, a safe level
for microcystins in BGA products was deter-
mined tobe 1 pg/g. This levelwas adopted by
the ODA as a regulatory standard for BGA
products on 23 October 1997.
Discussion
Exposure to microcystins and other cyano-
bacterial toxins through the ingestion of
contaminated water or recreational contact is
receiving increasing attention around the
world as a public health concern (1-5).
Several countries (20,21,27), and recently
the World Health Organization (22), have
made recommendations regarding safe algal
toxin levels in drinking water and surface
waters usedfor recreation. In contrast, poten-
tial health risks from exposure to toxins in
health food products made from BGA have
received little attention (2,3,6,14). (Health
Canada issued an advisory for microcystins
in BGAproducts on 5 May 1999.) Although
the BGA in many health food products is
produced under cultured conditions-where
the growth oftoxin-producing cyanobacteria
can, at least the-oretically, be controlled-the
BGA in products from UKL are harvested
from an open environment where the
growth ofthe toxic BGA M. aeruginosa is a
regular occurrence. Because M aeruginosa
coexistswith A.pos-aquae, the target BGA, it
can be collected inadvertently during the
E 1.5
; 1.0
0.0 1U 15 20
Retentiontime(min)
Figure 2. HPLC-ELISA of microcystins in a BGA sample. The flow rate of HPLC was 1.0 mL/min. Fractions
(0.5 mI/tube) were collected from the HPLC column and analyzed by ELISA. (A) The actual MCYST con-
centrations in each fraction, as determined by ELISA. (B) The inverse peak generated by plotting the
absorbance readings for each fraction obtained from ELISAagainstthe retention time.
harvesting process, resulting in contamina-
tion ofBGAproducts.
In fall 1996, a large bloom ofM aerugi-
nosa in UKL prompted the OHD and the
ODAto establish aregulatorylimitformicro-
cystin toxins in BGA products and to test
these products for the presence ofmicrocystin
toxins. Using established risk assessment
methodology, OHD investigators derived a
safe microcystin level of 1 pg/g in BGAprod-
ucts. This level was adopted as a regulatory
standard by the ODA on 23 October 1997
for BGA products sold in Oregon. The level
is directlycomparable to the 1 pg/L drinking
water guideline level (based on a daily water
intake of 2 L) recently promulgated by the
World Health Organization (22). Analysis of
UKL BGA products using ELISA found
microcystins in 85 ofthe 87 products tested,
with levels ranging up to 16.4 pg/g. Sixty-
three samples (72%) had microcystin con-
centrations > 1 pg/g. HPLC separation and
ELISA analysis of selected samples showed
that the predominant microcystin (> 90%)
was MCYST-LR, which is considered the
most toxicmicrocystinvariant.
Because ofthe known hepatotoxic poten-
cy ofmicrocystins, the presence ofthese tox-
ins in food products is cause for concern. The
toxicity of microcystins has been extensively
studied (27-31). After ingestion, microcystins
are actively taken into the portal circulation
from the digestive tract and rapidly cleared
from the plasma via active transport into
hepatocytes (32-35). Once inside hepato-
cytes, microcystins tightly bind and inhibit
protein phosphatase 1 and 2A (PP1 and
PP2A), resulting in the hyperphosphorylation
ofcellular proteins with critical roles in the
maintenance of cell structure and function
(31-34,36). Acute exposure to high micro-
cystin doses results in severe damage to the
hepatocyte cytoskeleton, causing morphologic
changes in hepatocytes and sinusoids and,
ultimately, intrahepatic hemorrhage and
hypovolemicshock(7,14,28).
Although less is known about the possi-
ble health effects from exposure to lower
doses ofmicrocystins, there is increasing con-
cern that chronic exposure to low levels may
also pose a significant health risk. Potential
tumor promotion is a primary concern
(14,29,37-3_l). Microcystins are believed to
promote tumor formation through the inhi-
bition ofPP1 and PP2A, which are integrally
Table 3. Microcystin concentrations in Spirulina
blue-green algae dietarysupplements.a
Sample date MCYST(pg/g)
1998 0.15 ± 0.08b(0.06-0.32; 8)c
1999 0.52 ± 0.77 (0.0-2.12; 7)
aSamples collected by the ODA (May 1998 and January
1999). b'Values are means ± SD. cValues in parentheses
are range and number(n) ofsamplesanalyzed.
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involved in cell-cycle regulation (14,29,39).
This mechanism of tumor promotion has
been well characterized in the diarrhetic shell-
fish poison toxin okadaic acid (39,40). Evi-
dence for tumor promotion by microcystins
has been provided in animal (30,38,39) and
epidemiologic (14,39,41-43) studies. Recent
work suggests that the high incidence ofpri-
mary liver cancer in China may be due, in
part, to chronic exposure to microcystins in
drinkingwater (39,41-43).
Continuous low-level exposure to micro-
cystins may also result in hepatic accumula-
tion. Studies have shown that, once taken up
by the liver, microcystin excretion occurs
very slowly (31,34,35). Bioaccu-mulation of
microcystins has been demonstrated in labo-
ratory animals (31) and in aquatic verte-
brates and invertebrates (44). These results
raise concerns that long-term exposure to
even very low levels of microcystins may be
significant, and could ultimately result in
livercancer and other liverdiseases.
Although it is widely recognized that
exposure to microcystins in drinking water
represents a significant health risk, the
potential for microcystin exposure may be
substantially greater for consumers of BGA
products. Because M aeruginosa blooms are
seasonal events, microcystin concentrations
in surface waters tend to be sporadic, thus
allowing for regular clearing ofmicrocystins
from the liver and recovery from possible
injury. However, BGA for use in dietary
supplements is harvested during the bloom
season and is then processed and distributed
all year. Thus, ifthe BGA is contaminated
with microcystins, the toxin exposure is con-
tinuous throughout the year. In addition, the
intake oftoxins from drinking water is natu-
rally limited by water consumption rates
(average 1.5-2 L/day), whereas there is virtu-
ally no limit to how much BGA can be
consumed. Users of these products have
reported consumption rates ofas much as 20
g/day. Thus, potential exposure to micro-
cystin toxins in BGA products is much
greater than exposure through drinkingwater.
Concerns regarding the potential micro-
cystin contamination ofUKL BGA products
also raised concerns about the safety ofother
BGA products, including those containing
Spirulina. Spirulina is a commonly consumed
BGA that is grown under cultured conditions
(3). Contamination of UKL BGA products
occurs because the BGA is harvested from an
open lake environment where other
cyanobacteria can grow freely; thus, it would
be expected that contamination ofSpirulina
and other cultured BGAwould be less likely.
The present test results, showing low levels of
microcystins in Spirulina products, appear to
support this conclusion. However, although
cultured growing conditions provide the
opportunity for carefuil monitoring and con-
trol oftoxic algal growth, there is no guaran-
tee that such monitoring and control actually
occurs. Without clear regulatory standards
for microcystins and other potential contami-
nants, the purityofany BGAproduct cannot
be assured.
Some BGA harvesters have reportedly
made an effort to reduce the microcystin
content oftheir products. The lower micro-
cystin levels in the ODAJanuary 1999 sam-
pling (Table 1) suggest that the industry
may be having some success in this regard.
However, environmental conditions at UKL
in 1997 and 1998 were less conducive to M
aeruginosa growth than conditions in 1996,
and it is possible the decreased microcystin
levels are due, at least in part, to reduced M
aeruginosagrowth.
A key element for ensuring the safety of
BGA products is adequate product testing
and batch characterization. The distribution
of M. aeruginosa and microcystin toxin in
lakes can be markedly variable both tempo-
rally and spatially (18). Results in Table 1
clearly indicate a wide range of MCYST in
the samples analyzed. It is likely this variation
is due largely to seasonal differences. Routine
testing has shown that MCYST levels in
BGA products varies greatly with the time of
harvest (45). For example, BGA harvested
during periods of heavy M. aeruginosa
blooms (July-September) contains the
highest levels oftoxins, whereas MCYST lev-
els in BGA harvested in the late fall
(October-November) is generally very low.
In addition to temporal factors, the micro-
cystin content in BGA products may also be
influenced byspatialvariability. In the present
study, a comparison of microcystin concen-
trations in individual and composite samples
from the same BGA product containers
found that in most cases the variation was
< 30%; however, because preliminary data
showed differences within some product sam-
ples ofup to 99%, we further investigated the
potential for batch heterogeneity. A compari-
son oftwo samples from each ofsix different
batches found unremarkable differences in
most ofthe samples, but found a large differ-
ence (> 100%) in one sample.
Historically, batch designations by the
UKL BGA industry have been somewhat
arbitrary and have differed significantly
among harvesters. In some cases, harvesters
have relied on a single microcystin analysis
for each batch, assuming batch homogeneity.
The present findings suggest that batch
homogeneity cannot always be assumed, and
underscore the need for adequate batch char-
acterization. Overall, these results indicate
that microcystin contamination of BGA
products can be variable, and that regular
monitoring, extensive testing, and thorough
batch mixing is necessary to ensure the safety
ofBGAproducts.
BGA products and other dietary supple-
ments are regulated by the U.S. Food and
DrugAdministration (FDA) under the 1994
Dietary Supplement Health and Education
Act (DSHEA) (46). Under this law, the
manufacturers of dietary supplements can
market their products without having to
demonstrate the product's safety to the FDA
(47-49). Once a dietary supplement is mar-
keted, the FDA cannot take action against a
product unless it can demonstrate that the
product is unsafe (49,50). For information
regarding the safety of dietary supplements,
the FDA relies heavily on reports to its
MedWatch program (51). Although this
program provides useful information to the
FDA, it has several limitations. It is a passive
system, and thus only a small percentage of
adverse events are recorded. It is also more
useful foridentifying short-term overt effects
(e.g., cardiac arrest associated with ephed-
rine-containing products) than long-term
effects such as liver cancer and other chronic
diseases. It is also likely that many potential-
ly adverse events go unrecognized. For
example, one reported effect of low-level
exposure to microcystins is gastrointestinal
(GI) disturbance (2,3,5), and GI disturbance
is apparently a fairly common experience of
BGA consumers. MedWatch has received
several reports ofnausea, vomiting, and diar-
rhea associated with BGA consumption
(51). Although GI disturbance is acknowl-
edged by the BGA industry as a potential
consequence of BGA consumption, it is
attributed to "detoxification" ofthe body.
Many consumers ofdietary supplements
and other alternative health care products
assume that these products could not be sold
without the absolute assurance of safety.
Unfortunately, because of the regulatory
limits on the FDA that are imposed by the
DSHEA, this is not the case. As our work
with UKL BGA demonstrates, the dietary
supplement industry is largely self-regulated,
and assuming that these products are entirely
safe maynot, in fact, be asafe assumption.
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